Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired activated protein C resistance in sarcoma patients.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis - 1 Jul 2012

Soyer Nur, Kececi Burcin, Eroglu Zuhal, Kamer Serra, Ozcelik Cagri, Cagirgan Seckin, Tombuloglu Murat, Sabah Dundar, Donmez Ayhan

Abstract excerpt

Acquired activated protein C resistance (aAPCR) is seen more frequently in solid and hematological cancer patients. We aimed to investigate the presence of aAPCR and the frequency of clinically detectable thrombosis in sarcoma patients. Normalized activated protein C sensitivity ratio (nAPCSR), factor V Leiden (FVL) mutation, factor V (FV) levels and factor VIII (FVIII) levels were prospectively measured in 52...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activated Protein C Resistance
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Neoplasms

Share to Factor V

Share to Factor VIII

Share to Sarcoma

Share to Time Factors

Share to Venous Thromboembolism

Source

Identifiers

PMID: 22576290
DOI: 10.1097/MBC.0b013e3283548e19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired activated protein C resistance in sarcoma patients.PMID 22576290Read ↗

Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.Semantic proximity Read ↗

Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer.Semantic proximity Read ↗

Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS).Semantic proximity Read ↗

Resistance to activated protein C due to factor V R506Q mutation as a cause of venous thrombosis.Semantic proximity Read ↗

Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients.Semantic proximity Read ↗

Factor V mutations in Iranian patients with activated protein C resistance and venous thrombosis.Semantic proximity Read ↗

Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial.Semantic proximity Read ↗

Activated-protein-C resistance in cancer patients.Semantic proximity Read ↗

Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.Semantic proximity Read ↗

High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia.Semantic proximity Read ↗

Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation.Semantic proximity Read ↗

Incidence and clinical manifestations of activated protein C resistance and factor V Leiden in young patients with venous thromboembolic disease in Spain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.